ARKG vs SLV

ARK Genomic Revolution ETF vs iShares Silver Trust

Quick take
  • • SLV has the lower expense ratio at 0.50% vs 0.75% for ARKG.

Side-by-side metrics

MetricARKGSLV
Expense ratio
Annual fee. Lower is better.
0.75%0.50%
Dividend yield
Trailing 12-month yield.
0.00%0.00%
AUM
Assets under management — bigger funds are typically more liquid.
$2.21B$25.19B
YTD return
66.55%-25.27%
1-year return
——
3-year return
Annualized.
——
5-year return
Annualized.
——
10-year return
Annualized.
——
Beta (3Y)
Volatility relative to the market. Closer to 1 = market-like.
2.111.26
P/E ratio
——
Last price
$47.17$46.92
Inception
——
Issuer
ARKiShares

ARKG top holdings

Top holdings · ARKG
TWSTTwist Bioscience Corp8.75%
TXG10x Genomics Inc Ordinary Shares - Class A8.73%
TEMTempus AI Inc Class A common stock8.36%
ABSIAbsci Corp5.56%
CRSPCRISPR Therapeutics AG5.22%
GHGuardant Health Inc4.88%
NTRANatera Inc4.71%
ILMNIllumina Inc4.69%
LLYEli Lilly and Co3.92%
BEAMBeam Therapeutics Inc3.69%
Sector breakdown · ARKG
Healthcare100.0%

SLV top holdings

Holdings data unavailable for SLV.

About ARKG

ARKG (ARK Genomic Revolution ETF) is Companies advancing genomics and molecular biology. Managed by ARK, the fund carries $2.2B in assets under management, an expense ratio of 0.75%. Its largest holding is Twist Bioscience Corp (TWST), which represents 8.7% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.

About SLV

SLV (iShares Silver Trust) is Physically backed silver ETF. Managed by iShares, the fund carries $25.2B in assets under management, an expense ratio of 0.50%.